Atossa Genetics (ATOS) Opens Enrollment for Fulvestrant Phase 2 in Breast Cancer

March 2, 2016 8:03 AM EST Send to a Friend
Atossa Genetics Inc. (Nasdaq: ATOS) announced today that the "007" trial, a Phase 2 study in women with ductal carcinoma ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login